TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01344135

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation
Description: Phase A, Rehabilitation (4 months): 3 nutritional supplements daily~Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)~Phase C, Follow-up (3 months): no supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily~Phase B, Maintenance (8 months): No supplementation~Phase C, Follow-up (3 months): No supplementation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Phase A, Rehabilitation (4 months): No counselling~Phase B, Maintenance (8 months): Nutritional counselling (4x)~Phase C, Follow-up (3 months): No counselling~Aim:~1. Optimising dietary intake to physical activity pattern and energy expenditure.~2. Minimize deterioration of dietary intake during acute exacerbations.~3. Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.~4. Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Feedback on physical activity level
Description: Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~1. Integration of exercise behaviour into daily routine~2. Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~3. Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback on physical activity level
Description: Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~1. Integration of exercise behaviour into daily routine~2. Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~3. Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle
Study: NCT03925896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP2 Antigen-specific TCR T cells
Description: All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
Study: NCT00486681

Intervention type: DEVICE
Intervention: Accu Chek Inform and Cobas IT 1000
Description: period II (warning activated)
Study: NCT02265965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous nitroglycerin
Description: Infusion at started at time of hysterotomy and stopped at neonate delivery
Study: NCT04583982

Intervention type: OTHER
Intervention: T-Detect™ SARS-CoV-2 Assay
Description: T-Detect™ SARS-CoV-2 Assay is an investigational device that is indicated to assess T-cell immune response to SARS-CoV-2 via the testing of blood samples from patients with signs and symptoms of suspected COVID-19. These results will not be shared with the participant.
Study: NCT00060411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT00207740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO148
Description: Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
Study: NCT02332265

Intervention type: OTHER
Intervention: Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)
Description: The SAFE program was developed \& implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, \& Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission \& partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices \& sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings \& Loans Groups, 3) building capacity of local governance structures \& 4) integrating HIV education \& gender empowerment into programs through training \& education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.

Intervention type: OTHER
Intervention: Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)
Description: The SAFE program was developed \& implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, \& Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission \& partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices \& sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings \& Loans Groups, 3) building capacity of local governance structures \& 4) integrating HIV education \& gender empowerment into programs through training \& education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
Study: NCT02390232

Intervention type: BIOLOGICAL
Intervention: liver biopsy
Description: A small needle is inserted into the liver to collect a tissue sample

Intervention type: BIOLOGICAL
Intervention: liver biopsy
Description: A small needle is inserted into the liver to collect a tissue sample

Intervention type: BIOLOGICAL
Intervention: collection of stools
Description: collection of stools

Intervention type: BIOLOGICAL
Intervention: collection of stools
Description: collection of stools

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: collection of blood sample

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: collection of blood sample
Study: NCT02305264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DPA-714 and 18F-FDG
Description: Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter.
Study: NCT03881436

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI with DTI sequence
Description: At the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography DTI sequence

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI with DTI sequence
Description: At the end of the planned sequence, but before any contrast agent injection:~* Acquisition of a an additional anatomical T2 SPACE sequence~* Acquisition of a tractography DTI sequence
Study: NCT00128128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice cocktail
Description: Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice cocktail
Description: Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry juice cocktail
Description: Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry juice cocktail
Description: Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
Study: NCT03207399

Intervention type: DRUG
Group type: OTHER
Intervention: Epclusa
Description: Patients will be treated with this drug for 12 weeks post lung transplant.
Study: NCT02552927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest shield with aluminum foil (CALF)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHIELD
Study: NCT04739228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Written Disclosure Protocol Group
Description: The writing task consists of three sessions of 20 minutes each, with an interval of one week between each other. In the first session, patients were asked to describe the onset of illness, describing chronologically and detailed places, images, sounds and actions, as they are followed and detached from the emotions. In the second session, the patients were asked to write about thoughts and emotions felt during the illness experience, talking about the impact that illness had on their daily lives and how it had changed their personal attitude to life itself. In the third and final session, the patients were asked to analyze subjective new skills acquired.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: The writing task also consists of three sessions of 20 minutes each, with an interval of one week between each other. In all three writing sessions, patients were asked to report the daily activities during the last week, without focusing on the emotional aspects.
Study: NCT00835718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0594 5 mg/day
Description: MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0594 1 mg/day
Description: MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0594 1 mg/week
Description: MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to MK0594
Description: Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to MK0594
Description: Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
Study: NCT03812419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40 mg
Description: Esomeprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole 40mg
Description: Pantoprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
Study: NCT01836237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexis - a wound protector
Description: Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
Study: NCT02073786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lightwand intubation
Description: Conventional lightwand intubation technique will perform during intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid video stylet
Description: Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
Study: NCT02536911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT00599560

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: vasopressin, V2 receptor and cyclic AMP
Description: plasma vasopressin, V2 receptor, cyclic AMP
Study: NCT04620499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: PEER EEG
Study: NCT02457975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 670nm PBM
Description: Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreous VEGF-inhibitors
Description: Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravitreous VEGF-inhibitors
Description: Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
Study: NCT04463134

Intervention type: DRUG
Intervention: NTM drug treatment
Description: NTM drug treatment according to guideline and sensitivity test results
Study: NCT02051868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Description: 5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
Study: NCT00477009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular repositioning appliance, adjustable
Description: Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mandibular repositioning appliance, adjustable
Description: Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
Study: NCT00496418

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh in permanent colostomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh in permanent colostomy
Study: NCT01417169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting \<50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
Study: NCT00706563

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: Single intramuscular dose on Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: Single intramuscular dose on Day 0
Study: NCT03311191

Intervention type: DEVICE
Intervention: Measurement of skin oxygenation and oxygen consumption
Description: Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.

Intervention type: DEVICE
Intervention: Measurement of skin oxygenation and oxygen consumption
Description: Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.

Intervention type: DEVICE
Intervention: Measurement of skin oxygenation and oxygen consumption
Description: Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.

Intervention type: DEVICE
Intervention: Measurement of skin oxygenation and oxygen consumption
Description: Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
Study: NCT03071601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Prilocaine Cream 2.5-2.5%
Description: Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% Epinephrine 0.005mg/mL solution
Description: Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
Study: NCT00251758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Study: NCT04087512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on perturbation treadmill
Description: Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises of dynamic stability under unstable conditions
Description: The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
Study: NCT04366674

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cleft palate repair
Description: restoration of tensor veli palatini for the purpose of the muscle function recovery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleft palate repair
Description: restoration of tensor veli palatini for the purpose of the muscle function recovery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cleft palate repair
Description: restoration of tensor veli palatini for the purpose of the muscle function recovery.
Study: NCT04596904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender oil application group
Description: Individuals, for 10 days, 3 drops of cotton drops of lavender oil, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water application group
Description: Individuals, for 10 days, 3 drops of cotton drops of distilled water, put on the shoulder parts, between 21:00 and 21:05 will smell every evening.
Study: NCT02865863

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eurycomalongifoliawater extract (Physta®)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin